Randomised controlled trial of non-invasive ventilation (N IV) for nocturnal hypoventilation in neuromuscular and chest wall disease patients with daytime normocapnia

Ward, S.; Chatwin, M.; Heather, S.; Simonds, A. K.
December 2005
Thorax;Dec2005, Vol. 60 Issue 12, p1019
Academic Journal
Background: Long term non-invasive ventilation (NIV) reduces morbidity and mortality in patients with neuromuscular and chest wall disease with hypercapnia ventilatory failure, but preventive use has not produced benefit in normocapnic patients with Duchenne muscular dystrophy. Individuals with nocturnal hypercapnia but daytime normocapnia were randomised to a control group or nocturnal NIV to examine whether nocturnal hypoventilation is a valid indication for NIV. Methods: Forty eight patients with congenital neuromuscular or chest wall disease aged 7-51 years and vital capacity <50% predicted underwent overnight respiratory monitoring. Twenty six with daytime normocapnia and nocturnal hypercapnia were randomised to either nocturnal NW or to a control group without ventilatory support. NIV was started in the control group if patients fulfilled preset safely criteria. Results: Peak nocturnal transcutaneous carbon dioxide tension (TcCO2) did not differ between the groups, but the mean (SD) percentage of the night during which TcCO2 was >6.5 kPa decreased in the NIV group (-57.7 (26.1)%) but not in controls (-11.75 (46.1)%; p=0.049, 95% Cl -91.5 to -0.35). Mean (SD) arterial oxygen saturation increased in the NIV group (+2.97 (2.57)%) but not in controls (-1.12 (2.02)%; p=0.024, 95% Cl 0.69 to 7.5). Nine of the 10 controls failed nonintervention by fulfilling criteria to initiate NIV after a mean (SD) of 8.3 (7.3) months. Conclusion: Patients with neuromuscular disease with nocturnal hypoventilation are likely to deteriorate with the development of daytime hypercapnia and/or progressive symptoms within 2 years and may benefit from the introduction of nocturnal NIV before daytime hypercapnia ensues.


Related Articles

  • Characteristics of Japanese Duchenne and Becker muscular dystrophy patients in a novel Japanese national registry of muscular dystrophy (Remudy). Nakamura, Harumasa; Kimura, En; Mori-Yoshimura, Madoka; Komaki, Hirofumi; Matsuda, Yu; Goto, Kanako; Hayashi, Yukiko K.; Nishino, Ichizo; Takeda, Shin'ichi; Kawai, Mitsuru // Orphanet Journal of Rare Diseases;2013, Vol. 8 Issue 1, Special section p1 

    Background: Currently, clinical trials for new therapeutic strategies are being planned for Duchenne and Becker muscular dystrophies (DMD/BMD). However, it is difficult to obtain adequate numbers of patients in clinical trials. As solutions to these problems, patient registries are an important...

  • SNT-MC17 PHASE IIA FOR MUSCULAR DYSTROPHY ENCOURAGING.  // Worldwide Biotech;Dec2007, Vol. 19 Issue 12, p5 

    The article reports that positive, first results from a 12 month Phase IIa clinical trial with SNT-MC17 in Duchenne Muscular Dystrophy (DMD) as measured by cardiac and respiratory parameters was announced by Santhera Pharmaceuticals, a Swiss specialty pharmaceutical company focused on...

  • Quantitative MRI and loss of free ambulation in Duchenne muscular dystrophy. Fischmann, Arne; Hafner, Patricia; Gloor, Monika; Schmid, Maurice; Klein, Andrea; Pohlman, Urs; Waltz, Tanja; Gonzalez, Rocio; Haas, Tanja; Bieri, Oliver; Fischer, Dirk // Journal of Neurology;Apr2013, Vol. 260 Issue 4, p969 

    The purpose of this ethics approved trial was to correlate quantitative MRI with functional abilities in both ambulant and non-ambulant Duchenne muscular dystrophy (DMD). Twenty patients with genetically confirmed DMD were recruited. Physical assessment was performed using the motor function...

  • Ongoing therapeutic trials and outcome measures for Duchenne muscular dystrophy. Govoni, Alessandra; Magri, Francesca; Brajkovic, Simona; Zanetta, Chiara; Faravelli, Irene; Corti, Stefania; Bresolin, Nereo; Comi, Giacomo P. // Cellular & Molecular Life Sciences;Dec2013, Vol. 70 Issue 23, p4585 

    Muscular dystrophy is a heterogeneous group of genetic disorders characterised by progressive muscle tissue degeneration. No effective treatment has been discovered for these diseases. Preclinical and clinical studies aimed at the development of new therapeutic approaches have been carried out,...

  • L-CARNITINE SUPPLEMENTATION IN DUCHENNE MUSCULAR DYSTROPHY STEROIDNAÏVE PATIENTS: A PILOT STUDY. Escobar-Cedillo, Rosa E.; Tintos-Hernández, Jesús A.; Martínez-Castro, Guadalupe; de Oca-Sánchez, Beatriz Montes; Rodríguez-Jurado, Rodolfo; Miranda-Duarte, Antonio; Lona-Pimentel, Socorro; Gómez-Díaz, Benjamín; Coral-Vázquez, Ramón M.; García, Silvia; López-Hernández, Luz B. // Current Topics in Nutraceutical Research;Aug2013, Vol. 11 Issue 3, p97 

    Duchenne muscular dystrophy (DMD) is a genetic neuromuscular disorder characterized by progressive weakness leading to disability. Steroid administration and physiotherapy are the most useful medical interventions in ambulant patients; In DMD, muscles present a significant deficiency of...

  • Current and emerging treatment strategies for Duchenne muscular dystrophy. Mah, Jean K. // Neuropsychiatric Disease & Treatment;Jul2016, Vol. 12, p1795 

    Duchenne muscular dystrophy (DMD) is the most common form of muscular dystrophy in childhood. It is caused by mutations of the DMD gene, leading to progressive muscle weakness, loss of independent ambulation by early teens, and premature death due to cardiorespiratory complications. The...

  • Targeting RNA to treat neuromuscular disease. Muntoni, Francesco; Wood, Matthew J. A. // Nature Reviews Drug Discovery;Aug2011, Vol. 10 Issue 8, p621 

    The development of effective therapies for neuromuscular disorders such as Duchenne muscular dystrophy (DMD) is hampered by considerable challenges: skeletal muscle is the most abundant tissue in the body, and many neuromuscular disorders are multisystemic conditions. However, despite these...

  • A mixed methods study of age at diagnosis and diagnostic odyssey for Duchenne muscular dystrophy. Wong, Siaw H; McClaren, Belinda J; Archibald, Alison Dalton; Weeks, Alice; Langmaid, Tess; Ryan, Monique M; Kornberg, Andrew; Metcalfe, Sylvia A // European Journal of Human Genetics;Oct2015, Vol. 23 Issue 10, p1294 

    The delayed diagnosis of Duchenne muscular dystrophy (DMD) may be an ongoing problem internationally. We aimed to ascertain age at diagnosis and explore parents' experiences of the diagnosis of DMD in Australia. Using mixed methods, data were collected from laboratory and clinical record audits...

  • Lack of Functional Benefit with Glutamine versus Placebo in Duchenne Muscular Dystrophy: A Randomized Crossover Trial. Mok, Elise; Letellier, Guy; Cuisset, Jean-Marie; Denjean, André; Gottrand, Frédéric; Alberti, Corinne; Hankard, Régis // PLoS ONE;2009, Vol. 4 Issue 5, p1 

    Background: Oral glutamine decreases whole body protein breakdown in Duchenne muscular dystrophy (DMD). We evaluated the functional benefit of 4 months oral glutamine in DMD. Methodology/Principal Findings: 30 ambulant DMD boys were included in this double-blind, randomized crossover trial with...


Read the Article


Sign out of this library

Other Topics